Use of thromboelastrography for monitoring NOACs

  • Research type

    Research Study

  • Full title

    To evaluate and use thromboelastography (TEG) test for measuring and monitoring non-Vitamin K antagonist oral anticoagulant (NOACs) in patients with long term anticoagulant therapy

  • IRAS ID

    198348

  • Contact name

    Khalid Saja

  • Contact email

    Khalid.Saja@bhrhospitals.nhs.uk

  • Sponsor organisation

    University Of Greenwich

  • Duration of Study in the UK

    0 years, 3 months, 10 days

  • Research summary

    Three new oral anticoagulants,(NOACs) namely,dabigatran,rivaroxaban and apixaban are licensed by the national institute for clinical excellence(NICE) for treatment and prevention of strokes and systemic embolism in patients with non-valvular arterial fibrillation. Even though routine coagulation monitoring of these drugs are not recommended,patient's kidney and liver function are very important for efficient metabolism and to maintain effective therapeutic level. Many laboratory coagulation technologies failed to measure these drugs,however measurement of these drugs is important to optimize dose to increase efficacy/or safety of patient,to ensure patient adhere to treatment,to establish dose is in the therapeutic range for effective drug action in emergency or urgent surgery and to prevent bleeding and amongst others. The study will use thromboelastrography(TEG) technology, to measure coagulation patterns of patient's blood on apixaban and try to relate it to patient's kidney and liver functions as well as their bleeding episodes and try to obtain theurapeutics levels to optimise dose for each patient groups. The study will be conducted in the Queen's Hospital laboratory from blood samples taken from all adult patients already taking apixaban. Citrate(coagulation) sample will be taken as part of blood samples at routine anticoagulant clinic. One millilitre(1ml) of the sample will be used mainly for RapidTEG and Kaolin TEG. The study is estimated to last for approximately three months. The study is identified as part of service improvement
    for the anticoagulation department of the trust.

  • REC name

    Yorkshire & The Humber - Leeds West Research Ethics Committee

  • REC reference

    16/YH/0044

  • Date of REC Opinion

    1 Feb 2016

  • REC opinion

    Unfavourable Opinion